The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer‐specific survival

• DOI: 10.1002/pros.23513
• Publication Date: 2018-03-31T05:10:23Z
• Authors: Vincent Q. Trinh; Jennifer Sirois; Nazim Benzerdjeb; Babak K. Mansoori; Andrée‐Anne Grosset; Roula Albadine; Mathieu Latour; Anne‐Marie Mes‐Ma...; Hélène Hovington; Alain Bergeron; Martin Ladouceur; Yves Fradet; Fred Saad; Dominique Trudel
• Keywords: Log-rank test; Grading (engineering)

Background To investigate the effect of intraductal carcinoma prostate (IDC‐P) in radical prostatectomy (RP) specimens context site recurrence, time to and cancer‐specific survival two academic cohorts locally, regionally, or distantly recurrent cancer. Methods Our cohort included men enrolled into tissue repositories from 1993 2011, who were treated with first‐line RP later experienced local regional distant metastasis (together termed clinical CR). material was reviewed identify IDC‐P update grading current standards. The primary endpoint initial location CR. Secondary endpoints CR survival. Pearson's chi‐square, Welch's t ‐test, Mann‐Whitney U test Fisher's exact performed for univariate analyses. Multinomial logistic regression used multivariate Cancer‐specific analyzed generalized Wilcoxon Cox regression. Results Eighty‐five patients analysis. present 78.5% Center 1 70.0% 2 ( P = 0.547). independently associated at (multivariate odds ratio 6.27, 0.015). status did not affect recurrence; median without recurrence 53 months IDC‐P(+) 50 IDC‐P(−) 0.441). Distant metastases event had a 36% reduction compared recurrences 0.007). Additionally, prostatic‐bed radiotherapy (adjuvant salvage biochemical before metastasis) 25% mortality no 0.023). Similar observed subgroup when (29%, 0.050). Conclusions In our cohort, presence an independent factor CR, but have significant impact on Furthermore, metastatic showed statistically reduced radiotherapy. This also identified IDC‐P. Future large scale validation studies should take account confirm its disease progression.